Keyphrases
Rituximab
100%
Phase II Trial
100%
Acetylcholine Receptor Antibody
100%
Myasthenia Gravis
100%
Prednisone
60%
Placebo
60%
Steroid-sparing
40%
Randomized Double-blind
20%
Placebo-controlled
20%
B Cells
20%
Clinical Improvement
20%
2-cycles
20%
Targeted Treatment
20%
Efficacy Trial
20%
Clinical Assessment
20%
Safety Issues
20%
Clinically Meaningful Improvement
20%
Large Trials
20%
Futility Design
20%
Myasthenia Gravis Foundation of America
20%
Neuroscience
Myasthenia gravis
100%
Rituximab
100%
Cholinergic Receptor Antibody
100%
Placebo
80%
Prednisone
60%
B Cell
20%
Clinical Assessment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Myasthenia gravis
100%
Cholinergic Receptor Antibody
100%
Placebo
80%
Prednisone
60%
Immunology and Microbiology
Rituximab
100%
Cholinergic Receptor Antibody
100%
Myasthenia gravis
100%
Prednisone
60%
B Cell
20%